In-vitro comparison of erythromycin, lincomycin, and clindamycin.
The in-vitro antibacterial activities of erythromycin, lincomycin, and clindamycin, a new derivative of lincomycin, were compared. Clindamycin was always more active than lincomycin, and was either as active as erythromycin or more so against betahaemolytic streptococci, Streptococcus viridans, Str. pneumoniae, and erythromycin-sensitive Staphylococcus aureus. It was also fully active against most erythromycin-resistant strains of Staph. aureus. On the other hand, it was somewhat less active than erythromycin against Haemophilus influenzae and considerably less active than erythromycin against Str. faecalis and Neisseria gonorrhoeae.Clinical trials seem to be justified in infections with sensitive organisms for which erythromycin might have been indicated.
D001419:Bacteria / Q000187:drug effects*; D013293:Enterococcus faecalis / Q000187:drug effects; D004917:Erythromycin / Q000494:pharmacology*; D006027:Glycosides / Q000494:pharmacology; D006193:Haemophilus influenzae / Q000187:drug effects; D008034:Lincomycin / Q000494:pharmacology*; D009344:Neisseria gonorrhoeae / Q000187:drug effects; D011759:Pyrrolidines / Q000494:pharmacology; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects
D006027:Glycosides; D011759:Pyrrolidines; D004917:Erythromycin; D008034:Lincomycin